Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Rodriguez Cerdeira, Carmen ^a   Sanchez Blanco, Elena ^a   Molares Vila, Alberto ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALMODULIN; COMPLEMENT COMPONENT C5A; CORTICOSTEROID; CSY 0073; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; GAMMA INTERFERON; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPHILIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MACROCYCLIC COMPOUND; MACROLIDE; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; PIMECROLIMUS; PLATELET DERIVED GROWTH FACTOR; PSORALEN; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANTIINFECTIVE AGENT; TARGET OF RAPAMYCIN KINASE;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALOPECIA AREATA; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ATOPIC DERMATITIS; BEHCET DISEASE; CHOLANGITIS; CLINICAL TRIAL (TOPIC); CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DEGRANULATION; DERMATITIS; DISCOID LUPUS ERYTHEMATOSUS; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; ERYTHEMA NODOSUM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IRRITANT DERMATITIS; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LUPUS ERYTHEMATOSUS; LYMPHOCYTIC INFILTRATION; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROSACEA; SIGNAL TRANSDUCTION; SKIN ALLERGY; SKIN BIOPSY; SKIN DEFECT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ULTRAVIOLET A RADIATION; URTICARIA; VITILIGO; DRUG ANTAGONISM; DRUG DEVELOPMENT; INFLAMMATION; SKIN DISEASE;

ANTI-BACTERIAL AGENTS; CALCINEURIN; DRUG DISCOVERY; HUMANS; INFLAMMATION; MACROLIDES; SKIN DISEASES; TOR SERINE-THREONINE KINASES;

EID: 84870205621     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/563709     Document Type: Review

References (98)

1. Martín Ezquerra G., Sánchez Regaña M., Herrera Acosta E., Umbert Millet P., Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. Journal of Drugs in Dermatology 2006 5 4 334 336 2-s2.0-33748907250
2. Gupta A. K., Chow M., Pimecrolimus: a review. Journal of the European Academy of Dermatology and Venereology 2003 17 5 493 503 2-s2.0-0141650744 10.1046/j.1468-3083.2003.00692.x (Pubitemid 37138884)
3. Alzolibani A. A., Zedan K., Macrolides in chronic inflammatory skin disorders. Mediators of Inflammation 2012 2012 7 10.1155/2012/159354 159354
4. Czarnecka-Operacz M., Jenerowicz D., Topical calcineurin inhibitors in the treatment of atopic dermatitis-an update on safety issues. Journal of the German Society of Dermatology 2012 10 3 167 173 10.1111/j.1610-0387.2011.07791.x
5. Berk L., Mita M. M., Kreisberg J., Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. Cancer Chemotherapy and Pharmacology 2012 69 5 1369 1377 10.1007/s00280-011-1813-7
6. Krengel S., Satzger I., Alter M., Kapp A., Gutzmer R., Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus. Der Hautarzt 2012 63 7 573 576
7. Sugawara A., Sueki A., Hirose T., Nagai K., Gouda H., Hirono S., Shima H., Akagawa K. S., Õmura S., Sunazuka T., Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorganic and Medicinal Chemistry Letters 2011 21 11 3373 3376 2-s2.0-79956084563 10.1016/j.bmcl.2011. 04.004
8. Kanehisa M., Goto S., KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research 2000 28 1 27 30 2-s2.0-0033982936 (Pubitemid 30047706)
9. BioCarta-Charting Pathways of Life, http://www.biocarta.com/
10. Czarnecka-Operacz M., Jenerowicz D., Topical calcineurin inhibitors in the treatment of atopic dermatitis-an update on safety issues. Journal der Deutschen Dermatologischen Gesellschaft 2012 10 3 167 162
11. Wolff K., Fleming C., Hanifin J., Papp K., Reitamo S., Rustinn M., Shear N., Silny W., Korman N., Marks I., Cherill R., Emady-Azar S., Paul C., Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. British Journal of Dermatology 2005 152 6 1296 1303 2-s2.0-21644487962 10.1111/j.1365-2133.2005.06674.x (Pubitemid 40933432)
12. Naldi L., Rzany B., Chronic plaque psoriasis. Clinical Evidence 2005 13 2070 2098 2-s2.0-33644829855
13. Kalb R. E., Bagel J., Korman N. J., Lebwohl M. G., Young M., Horn E. J., Van Voorhees A. S., Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2009 60 1 120 124 2-s2.0-57649143888 10.1016/j.jaad.2008.06.041
14. Fabroni C., Lotti T., Pimecrolimus in dermatology. Giornale Italiano di Dermatologia e Venereologia 2009 144 3 321 325 2-s2.0-68849129427
15. Gottlieb A. B., Griffiths C. E. M., Ho V. C., Lahfa M., Mrowietz U., Murrell D. F., Ortonne J. P., Todd G., Cherill R., Marks I., Emady-Azar S., Paul C. F., Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. British Journal of Dermatology 2005 152 6 1219 1227 2-s2.0-21644486867 10.1111/j.1365-2133.2005.06661.x (Pubitemid 40933421)
16. Roopashree M. R., Gondhalekar R. V., Shashikanth M. C., George J., Thippeswamy S. H., Shukla A., Pathogenesis of oral lichen planus-a review. Journal of Oral Pathology and Medicine 2010 39 10 729 734 2-s2.0-77958595691 10.1111/j.1600-0714.2010.00946.x
17. López-Jornet P., Camacho-Alonso F., Salazar-Sanchez N., Topical tacrolimus and pimecrolimus in the treatment of oral lichen planus: an update. Journal of Oral Pathology and Medicine 2010 39 3 201 205 2-s2.0-77249115304 10.1111/j.1600-0714.2009.00830.x
18. Elad S., Epstein J. B., Yarom N., Drucker S., Tzach R., Von Bltzingslöwen I., Topical immunomodulators for management of oral mucosal conditions, a systematic review; part I: calcineurin inhibitors. Expert Opinion on Emerging Drugs 2010 15 4 713 726 2-s2.0-78649456532 10.1517/14728214.2010. 528389
19. van Geel N., Speeckaert R., Mollet I., In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell and Melanoma Research 2012 25 1 57 65 10.1111/j.1755-148X.2011.00922.x
20. Köse O., Arca E., Kurumlu Z., Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. Journal of Dermatological Treatment 2010 21 3 133 139 2-s2.0-77951096421 10.3109/09546630903266761
21. Wardhana, Datau E. A., Chronic autoimmune urticaria. Acta Medica Indonesiana 2012 44 2 165 174
22. Marsland A. M., Soundararajan S., Joseph K., Kaplan A. P., Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clinical and Experimental Allergy 2005 35 5 554 559 2-s2.0-20044386002 10.1111/j.1365-2222. 2005.02242.x (Pubitemid 40769276)
23. Kim M. B., Kim G. W., Park H. J., Pimecrolimus 1 cream for the treatment of rosacea. The Journal of Dermatology 2011 38 12 1135 1139 10.1111/j.1346-8138. 2011.01223.x
24. Ucak H., Kandi B., Cicek D., Halisdemir N., Dertlolu S. B., The comparison of treatment with clobetasol propionate 0.05 and topical pimecrolimus 1 treatment in the treatment of alopecia areata. The Journal of Dermatological Treatment 2011 25 7 345 249
25. Katoulis A., Georgala S., Bozi E., Papadavid E., Kalogeromitros D., Stavrianeas N., Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus. Journal of the European Academy of Dermatology and Venereology 2009 23 5 580 582 2-s2.0-63849171230 10.1111/j.1468-3083.2008.02963. x
26. Moschella S. L., Bolognia J. L., Jorizzo J. L., Rapini R. P., Neutrophilic dermatoses. Dermatology 2003 1 415 418
27. Bellini V., Simonetti S., Lisi P., Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1 [10]. Journal of the European Academy of Dermatology and Venereology 2008 22 1 113 115 2-s2.0-37749002266 10.1111/j.1468-3083.2007.02280.x
28. Carneiro J. R. M., Fuzii H. T., Kayser C., Alberto F. L., Soares F. A., Sato E. I., Andrade L. E. C., IL-2, IL-5, TNF- α and IFN- γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics 2011 66 1 77 82 2-s2.0-79952956550 10.1590/S1807- 59322011000100014
29. Barikbin B., Givrad S., Yousefi M., Eskandari F., Pimecrolimus 1 cream versus betamethasone 17-valerate 0.1 cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clinical and Experimental Dermatology 2009 34 7 776 780 2-s2.0-70349490416 10.1111/j.1365-2230.2008.03138.x
30. Hamzaoui A., Klii R., Harzallah O., Attig C., Mahjoub S., Behçet's disease in women. La Revue de Medecine Interne 2012 33 10 552 555 10.1016/j.revmed.2012.06.007
31. Chams-Davatchi C., Barikbin B., Shahram F., Nadji A., Moghaddassi M., Yousefi M., Davatchi F., Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. International Journal of Rheumatic Diseases 2010 13 3 253 258 2-s2.0-77955403936 10.1111/j.1756-185X.2010.01531.x
32. Schmook T., Kraft J., Benninghoff B., Nindl I., Roewert J., Ulrich C., Stockfleth E., Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus [4]. Bone Marrow Transplantation 2005 36 1 87 88 2-s2.0-21744441346 10.1038/sj.bmt.1704998 (Pubitemid 40946057)
33. Sakuma S., Higashi Y., Sato N., Sasakawa T., Sengoku T., Ohkubo Y., Amaya T., Goto T., Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). International Immunopharmacology 2001 1 6 1219 1226 2-s2.0-0035033217 10.1016/S1567-5769(01)00059-5 (Pubitemid 32434437)
34. Sakuma S., Kato Y., Nishigaki F., Sasakawa T., Magari K., Miyata S., Ohkubo Y., Goto T., FK506 potently inhibits T cell activation induced TNF- α and IL-1 β production in vitro by human peripheral blood mononuclear cells. British Journal of Pharmacology 2000 130 7 1655 1663 2-s2.0-0033852795 (Pubitemid 30611945)
35. Kim K. H., Kono T., Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas. International Journal of Dermatology 2011 50 9 1153 1161 10.1111/j.1365-4632. 2011.04881.x
36. Keaney T. C., Bhutani T., Sivanesan P., Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis. Journal of the America Academy of Dermatology 2012 67 4 636 641
37. Laino L., DiCarlo A., Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. Archives of Dermatology 2011 147 6 760 2-s2.0-79959438279 10.1001/archdermatol. 2011.120
38. Lin A. N., Innovative use of topical calcineurin inhibitors. Dermatologic Clinics 2010 28 3 535 545 2-s2.0-77953257855 10.1016/j.det.2010.03.008
39. Vogel S. A., Yentzer B., Davis S. A., Feldman S. R., Cordoro K. M., Trends in pediatric psoriasis outpatient health care delivery in the United States. Archives of Dermatology 2012 148 1 66 71 10.1001/archdermatol.2011.263
40. Madan V., Griffiths C. E. M., Systemic ciclosporin and tacrolimus in dermatology. Dermatologic Therapy 2007 20 4 239 250 2-s2.0-35649025418 10.1111/j.1529-8019.2007.00137.x (Pubitemid 350029313)
41. Goldstein A. T., Thaçi D., Luger T., Topical calcineurin inhibitors for the treatment of vulvar dermatoses. European Journal of Obstetrics Gynecology and Reproductive Biology 2009 146 1 22 29 2-s2.0-68349137825 10.1016/j.ejogrb.2009.05.026
42. Suys E., Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. Journal of the American Academy of Dermatology 2012 66 2 327 328 10.1016/j.jaad.2011.05.024
43. Baubion E., Doutre M. S., Beylot-Barry M., Oral lichen planus and treatment with topical tacrolimus rinse. Annales de Dermatologie et de Venereologie 2009 136 3 276 278 2-s2.0-63449131740 10.1016/j.annder.2008.10.031
44. Baubion E., Doutre M. S., Beylot-Barry M., Oral lichen planus and treatment with topical tacrolimus rinse. Annales de Dermatologie et de Venereologie 2009 136 3 276 278 2-s2.0-63449131740 10.1016/j.annder.2008.10.031
45. Katsarou A., Makris M., Papagiannaki K., Lagogianni E., Tagka A., Kalogeromitros D., Tacrolimus 0.1 vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. European Journal of Dermatology 2012 22 2 192 196 10.1684/ejd.2011.1615
46. Kathuria S., Khaitan B. K., Ramam M., Sharma V. K., Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1 tacrolimus ointment vs 0.05 fluticasone propionate cream. Indian Journal of Dermatology, Venereology and Leprology 2012 78 1 68 73 10.4103/0378-6323.90949
47. Goldman D., Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. Journal of the American Academy of Dermatology 2001 44 6 995 998 2-s2.0-0035013932 10.1067/mjd.2001.114739 (Pubitemid 32493451)
48. Garg G., Thami G. P., Clinical efficacy of tacrolimus in rosacea. Journal of the European Academy of Dermatology and Venereology 2009 23 2 239 240 2-s2.0-58449090925 10.1111/j.1468-3083.2008.02822.x
49. Thiers B. H., Topical tacrolimus: treatment failure in a patient with alopecia areata. Archives of Dermatology 2000 136 1 124 2-s2.0-0033971944 (Pubitemid 30038834)
50. Kuldeep C., Singhal H., Khare A. K., Mittal A., Gupta L. K., Garg A., Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. International Journal of Trichology 2011 3 1 20 24 10.4103/0974-7753.82123
51. Larsen C. G., Thyssen J. P., Pustular penile pyoderma gangrenosum successfully treated with topical tacrolimus ointment. Acta Dermato- Venereologica 2012 92 1 104 105 10.2340/00015555-1167
52. Marzano A. V., Trevisan V., Lazzari R., Crosti C., Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. Journal of Dermatological Treatment 2010 21 3 140 143 2-s2.0-77951111787 10.3109/09546630903268239
53. Altieri M., Vaziri K., Orkin B. A., Topical tacrolimus for parastomal pyoderma gangrenosum: a report of two cases. Ostomy Wound Management 2010 56 9 56 59 2-s2.0-77957199543
54. Sugano M., Shintani Y., Kobayashi K., Sakakibara N., Isomura I., Morita A., Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. Journal of Dermatology 2006 33 12 887 891 2-s2.0-33751359976 10.1111/j.1346-8138.2006.00203.x (Pubitemid 44813793)
55. Lampropoulos C. E., D'Cruz D. P., Topical calcineurin inhibitors in systemic lupus erythematosus. Therapeutics and Clinical Risk Management 2010 15 6 95 101
56. Suzuki K., Kameda H., Amano K., Nagasawa H., Takei H., Nishi E., Okuyama A., Tsuzaka K., Takeuchi T., Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatology International 2011 31 6 757 763 2-s2.0-79959999365 10.1007/s00296-010-1366-9
57. Marks D. J. B., Segal A. W., Innate immunity in inflammatory bowel disease: a disease hypothesis. Journal of Pathology 2008 214 2 260 266 2-s2.0-38549087476 10.1002/path.2291 (Pubitemid 351160162)
58. McSharry K., Dalzell A. M., Leiper K., El-Matary W., Systematic review: the role of tacrolimus in the management of Crohn's disease. Alimentary Pharmacology and Therapeutics 2011 34 11-12 1282 1294 10.1111/j.1365-2036.2011. 04873.x
59. Woo J., Wright T. M., Lemster B., Borochovitz D., Nalesnik M. A., Thomson A. W., Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice. Clinical and Experimental Immunology 1995 100 1 118 125 2-s2.0-0028963839
60. Rallis E., Economidi A., Verros C., Papadakis P., Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1. Journal of Drugs in Dermatology 2006 5 9 906 907 2-s2.0-33750942732
61. Dé Tran Q. H., Guay E., Chartier S., Tousignant J., Tacrolimus in dermatology. Journal of Cutaneous Medicine and Surgery 2001 5 4 329 335 2-s2.0-0034849587 10.1007/s102270000022 (Pubitemid 32843790)
62. Yalçinda F. N., Batiolu F., Ozdemir O., Penetration of topically applied tacrolimus into the aqueous humor in Behçet's disease. Annals of Ophthalmology 2007 39 1 15 17 2-s2.0-35648969610 10.1007/BF02697321 (Pubitemid 350027399)
63. Evereklioglu C., Managing the symptoms of Behçet's disease. Expert Opinion on Pharmacotherapy 2004 5 2 317 328 2-s2.0-1242341941 10.1517/eoph.5.2.317.26487 (Pubitemid 38219858)
64. Matsumura K., Nakase H., Chiba T., Efficacy of oral tacrolimus on intestinal Behcet's disease. Inflammatory Bowel Diseases 2010 16 2 188 189 2-s2.0-73949147972 10.1002/ibd.20970
65. Jubran R. F., Dinndorf P. A., Successful therapy of refractory graft versus host disease with tacrolimus and psoralen plus ultraviolet light. Therapeutic Drug Monitoring 1998 20 2 236 239 2-s2.0-0031977608 10.1097/00007691-199804000-00017 (Pubitemid 28163208)
66. Fortune K., Couriel D., Tacrolimus in hematopoietic stem cell transplantation. Expert Opinion on Drug Metabolism and Toxicology 2009 5 7 835 841 2-s2.0-67650729785 10.1517/17425250903044959
67. Sabry W., Le Blanc R., Labbé A. C., Sauvageau G., Couban S., Kiss T., Busque L., Cohen S., Lachance S., Roy D. C., Roy J., Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biology of Blood and Marrow Transplantation 2009 15 8 919 929 2-s2.0-67649601258 10.1016/j.bbmt.2009.04.004
68. Kettritz R., Goebel U., Fiebeler A., Schneider W., Luft F., The protean face of sarcoidosis revisited. Nephrology Dialysis Transplantation 2006 21 10 2690 2694 2-s2.0-33749625941 10.1093/ndt/gfl369 (Pubitemid 44542217)
69. Katoh N., Mihara H., Yasuno H., Cutaneous sarcoidosis successfully treated with topical tacrolimus. British Journal of Dermatology 2002 147 1 154 156 2-s2.0-0036063919 10.1046/j.1365-2133.2002.04727.x (Pubitemid 34779453)
70. Alijotas-Reig J., Garcia-Gimenez V., Vilardell-Tarre's M., Tacrolimus in the treatment of chronic and refractory late-onset immune-mediated adverse effects related to silicone injections. Dermatologic Surgery 2012 38 1 38 47 10.1111/j.1524-4725.2011.02221.x
71. Rosen T., The Propionibacterium acnes genome: from the laboratory to the clinic. Journal of Drugs in Dermatology 2007 6 6 582 586 2-s2.0-34548411698
72. Raloff J., Triggering autoimmune assaults. Science News 2008 173 10
73. Marsland A. M., Griffiths C. E. M., The macrolide immunosuppressants in dermatology: mechanisms of action. European Journal of Dermatology 2002 12 6 618 621 2-s2.0-0036860261 (Pubitemid 35440816)
74. Beretta L., Gingras A. C., Svitkin Y. V., Hall M. N., Sonenberg N., Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO Journal 1996 15 3 658 664 2-s2.0-0030066934 (Pubitemid 26044579)
75. Petruzzo P., Testelin S., Kanitakis J., First human face transplantation: 5 years outcomes. Transplantation 2012 93 2 236 240 10.1097/TP.0b013e31823d4af6
76. Kahan B. D., Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with De Novo use of sirolimus in combination with cyclosporine. Transplantation Proceedings 2008 40 10 S17 S20 2-s2.0-57649088471 10.1016/j.transproceed.2008.10.019
77. Mathew T. H., Van Buren C., Kahan B. D., Butt K., Hariharan S., Zimmerman J. J., A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. Journal of Clinical Pharmacology 2006 46 1 76 87 2-s2.0-29644443431 10.1177/0091270005282628 (Pubitemid 43021716)
78. Jia W., Sun V., Tran N., Choi B., Liu S. W., Mihm M. C., Phung T. L., Stuart Nelson J., Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: implications for effective port wine stain treatment. Lasers in Surgery and Medicine 2010 42 2 105 112 2-s2.0-77249103572 10.1002/lsm.20890
79. Kourembanas S., Hannan R. L., Faller D. V., Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. Journal of Clinical Investigation 1990 86 2 670 674 2-s2.0-0025050735 (Pubitemid 20271905)
80. Shweiki D., Itin A., Soffer D., Keshet E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992 359 6398 843 845 2-s2.0-0026485002 10.1038/359843a0
81. Guba M., Von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C. J., Zuelke C., Farkas S., Anthuber M., Jauch K. W., Geissler E. K., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine 2002 8 2 128 135 2-s2.0-0036174289 10.1038/nm0202-128 (Pubitemid 34155123)
82. Seufferlein T., Rozengurt E., Rapamycin inhibits constitutive p70(s6k) phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Research 1996 56 17 3895 3897 2-s2.0-0029794614 (Pubitemid 26284735)
83. Knight R. J., Villa M., Laskey R., Benavides C., Schoenberg L., Welsh M., Kerman R. H., Podder H., Van Buren C. T., Katz S. M., Kahan B. D., Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clinical Transplantation 2007 21 4 460 465 2-s2.0-34547450198 10.1111/j.1399-0012.2007.00668.x (Pubitemid 47161821)
84. Squarize C. H., Castilho R. M., Bugge T. H., Gutkind J. S., Accelerated wound healing by mTOR activation in genetically defined mouse models. PLoS ONE 2010 5 5 2-s2.0-77956283576 10.1371/journal.pone.0010643 e10643
85. Ormerod A. D., Shah S. A. A., Copeland P., Omar G., Winfield A., Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. British Journal of Dermatology 2005 152 4 758 764 2-s2.0-17644374126 10.1111/j.1365-2133.2005.06438.x (Pubitemid 40571311)
86. Fasolo A., Sessa C., Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opinion on Investigational Drugs 2011 20 3 381 394 2-s2.0-79951627404 10.1517/13543784.2011.541154
87. Frigerio E., Colombo M. D., Franchi C., Altomare A., Garutti C., Altomare G. F., Severe psoriasis treated with a new macrolide: everolimus. British Journal of Dermatology 2007 156 2 372 374 2-s2.0-33846189774 10.1111/j.1365-2133.2006.07602.x (Pubitemid 46095969)
88. Van Velsen S. G. A., Haeck I. M., Bruijnzeel-Koomen C. A. F. M., Severe atopic dermatitis treated with everolimus. Journal of Dermatological Treatment 2009 20 6 365 367 2-s2.0-72449156139 10.3109/09546630903085294
89. Mayerhofer M., Aichberger K. J., Florian S., Krauth M. T., Hauswirth A. W., Derdak S., Sperr W. R., Esterbauer H., Wagner O., Marosi C., Pickl W. F., Deininger M., Weisberg E., Druker B. J., Griffin J. D., Sillaber C., Valent P., Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB Journal 2005 19 8 960 962 2-s2.0-20444445152 10.1096/fj.04-1973fje (Pubitemid 40827717)
90. Wan X., Shen N., Mendoza A., Khanna C., Helman L. J., CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1 α /VEGF signaling. Neoplasia 2006 8 5 394 401 2-s2.0-33744829237 10.1593/neo.05820 (Pubitemid 43830746)
91. Furge K. A., MacKeigan J. P., Teh B. T., Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. The Lancet Oncology 2010 11 6 571 578 2-s2.0-77953536522 10.1016/S1470-2045(09)70380-8
92. Mencarelli A., Distrutti E., Renga B., Cipriani S., Palladino G., Booth C., Tudor G., Guse J. H., Hahn U., Burnet M., Fiorucci S., Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. European Journal of Pharmacology 2011 665 1-3 29 39 2-s2.0-79958267558 10.1016/j.ejphar.2011.04.036
93. Xavier R. J., Podolsky D. K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007 448 7152 427 434 2-s2.0-34547176642 10.1038/nature06005 (Pubitemid 47123518)
94. Seral C., Carryn S., Tulkens P. M., Van Bambeke F., Influence of P-glycoprotein and MRP effux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 2003 51 5 1167 1173 2-s2.0-0038101671 10.1093/jac/dkg223 (Pubitemid 36622073)
95. Sugawara A., Sueki A., Hirose T., Nagai K., Gouda H., Hirono S., Shima H., Akagawa K. S., Õmura S., Sunazuka T., Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorganic and Medicinal Chemistry Letters 2011 21 11 3373 3376 2-s2.0-79956084563 10.1016/j.bmcl.2011. 04.004
96. Rivera V. M., Squillace R. M., Miller D., Berk L., Wardwell S. D., Ning Y., Pollock R., Narasimhan N. I., Iuliucci J. D., Wang F., Clackson T., Ridaforolimus (AP23573; MK-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Molecular Cancer Therapeutics 2011 10 6 1059 1071 2-s2.0-79958698108 10.1158/1535-7163.MCT-10-0792
97. Hashemolhosseini S., Nagamine Y., Morley S. J., Desrivières S., Mercep L., Ferrari S., Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. Journal of Biological Chemistry 1998 273 23 14424 14429 2-s2.0-0032485937 10.1074/jbc.273.23.14424 (Pubitemid 28319162)
98. Rosenwald I. B., Kaspar R., Rousseau D., Gehrke L., Leboulch P., Chen-J. J., Schmidt E. V., Sonenberg N., London I. M., Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. Journal of Biological Chemistry 1995 270 36 21176 21180 2-s2.0-0029166967 10.1074/jbc.270.36.21176